Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elizabeth Cairns

Senior Writer

A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.

Latest From Elizabeth Cairns

Novartis Aims To Dominate Rare Renal Disorders

Fabhalta and atrasentan are odds-on for approval in C3 glomerulopathy and IgA nephropathy, respectively, but commercial success might be harder to come by.

Clinical Trials Renal

Zealand Investors DREAM On

New academic data on obesity therapy dapiglutide are a prelude to a more significant readout.

Companies Clinical Trials

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

GSK Tailors SWIFT Readout Towards Asthma Approval

The twice-yearly depemokimab will soon head to the regulators, but it will need to succeed repeatedly if it is to make the £3bn peak sales GSK is hoping for.

Clinical Trials Respiratory

Roche’s New Obesity Play Shows Early Promise

CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.

Clinical Trials Metabolic Disorders

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Companies Deals
See All